No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 206K | 723K | 473K | 654K | 342K |
| Revenue Growth % | - | - | - | 2.51% | -0.35% | 0.38% | -0.48% |
| Cost of Goods Sold | 0 | 900K | 65K | 289K | 26K | 121K | 70K |
| COGS % of Revenue | - | - | 0.32% | 0.4% | 0.05% | 0.19% | 0.2% |
| Gross Profit | 0 | -900K | 141K | 434K | 447K | 533K | 272K |
| Gross Margin % | - | - | 0.68% | 0.6% | 0.95% | 0.81% | 0.8% |
| Gross Profit Growth % | - | - | 1.16% | 2.08% | 0.03% | 0.19% | -0.49% |
| Operating Expenses | 323.94K | 15.43M | 20.36M | 50.41M | 48.86M | 41.07M | 33.37M |
| OpEx % of Revenue | - | - | 98.81% | 69.73% | 103.29% | 62.8% | 97.56% |
| Selling, General & Admin | 323.94K | 6.67M | 3.26M | 18.81M | 16.16M | 14.42M | 13.31M |
| SG&A % of Revenue | - | - | 15.83% | 26.02% | 34.17% | 22.05% | 38.91% |
| Research & Development | 6.64M | 8.76M | 15.2M | 28.42M | 31.92M | 26.66M | 20.06M |
| R&D % of Revenue | - | - | 73.81% | 39.3% | 67.48% | 40.76% | 58.65% |
| Other Operating Expenses | 0 | 0 | 1.89M | 3.18M | 773K | 0 | 0 |
| Operating Income | -323.94K | -16.33M | -20.21M | -49.98M | -48.41M | -40.54M | -33.09M |
| Operating Margin % | - | - | -98.13% | -69.13% | -102.34% | -61.99% | -96.76% |
| Operating Income Growth % | - | -49.42% | -0.24% | -1.47% | 0.03% | 0.16% | 0.18% |
| EBITDA | 348.06K | -15.43M | -19.25M | -49.02M | -47.39M | -38.84M | -31.45M |
| EBITDA Margin % | - | - | -93.45% | -67.8% | -100.19% | -59.38% | -91.95% |
| EBITDA Growth % | - | -45.34% | -0.25% | -1.55% | 0.03% | 0.18% | 0.19% |
| D&A (Non-Cash Add-back) | 672K | 900K | 963K | 955K | 1.02M | 1.71M | 1.65M |
| EBIT | 19.43K | -16.07M | -17.92M | -9.3M | -26.62M | -44.95M | -35.34M |
| Net Interest Income | 343.37K | -88K | -950K | -870K | -3.3M | -3.17M | -3.2M |
| Interest Income | 343.37K | 0 | 0 | 0 | 0 | 1.39M | 865K |
| Interest Expense | 0 | 88K | 950K | 870K | 3.3M | 4.56M | 4.06M |
| Other Income/Expense | 343.37K | 177K | 1.34M | 39.81M | 18.49M | -8.96M | -6.31M |
| Pretax Income | 19.43K | -16.16M | -18.87M | -10.17M | -29.92M | -49.5M | -39.4M |
| Pretax Margin % | - | - | -91.61% | -14.06% | -63.25% | -75.69% | -115.2% |
| Income Tax | 0 | 0 | 406K | -428K | 0 | 0 | 0 |
| Effective Tax Rate % | -14.27% | 1% | 1.02% | 0.96% | 1% | 1% | 1% |
| Net Income | -277.31K | -16.16M | -19.28M | -9.74M | -29.92M | -49.5M | -39.4M |
| Net Margin % | - | - | -93.58% | -13.47% | -63.25% | -75.69% | -115.2% |
| Net Income Growth % | - | -57.26% | -0.19% | 0.49% | -2.07% | -0.65% | 0.2% |
| Net Income (Continuing) | 19.43K | -16.16M | -19.28M | -9.74M | -29.92M | -49.5M | -39.4M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.09 | -4.69 | -5.51 | -3.16 | -4.69 | -9.43 | -5.67 |
| EPS Growth % | - | -51.76% | -0.17% | 0.43% | -0.48% | -1.01% | 0.4% |
| EPS (Basic) | -0.09 | -4.69 | -5.51 | -3.16 | -4.69 | -9.43 | -5.67 |
| Diluted Shares Outstanding | 3.12M | 3.47M | 3.5M | 3.08M | 3.26M | 5.25M | 6.95M |
| Basic Shares Outstanding | 3.12M | 3.47M | 3.5M | 3.08M | 3.26M | 5.25M | 6.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 790.48K | 9.48M | 62.99M | 54.58M | 29.2M | 38.85M | 16.16M |
| Cash & Short-Term Investments | 743.78K | 8.79M | 59.27M | 50.29M | 23.32M | 35M | 12.15M |
| Cash Only | 743.78K | 8.79M | 59.27M | 50.29M | 18.33M | 28.82M | 12.15M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 4.98M | 6.18M | 0 |
| Accounts Receivable | 0 | 0 | 2.17M | 1.61M | 2.97M | 1.34M | 391K |
| Days Sales Outstanding | - | - | 3.84K | 814.31 | 2.29K | 746.74 | 417.3 |
| Inventory | 0 | 28K | 191K | 41K | 43K | 37K | 68K |
| Days Inventory Outstanding | - | 11.36 | 1.07K | 51.78 | 603.65 | 111.61 | 354.57 |
| Other Current Assets | 0 | 248K | 112K | 2.45M | 2.87M | 2.48M | 137K |
| Total Non-Current Assets | 46.37M | 5.4M | 5.25M | 8.48M | 15.3M | 13.49M | 11.18M |
| Property, Plant & Equipment | 4.47M | 5.4M | 5.25M | 8.42M | 15.24M | 13.43M | 11.12M |
| Fixed Asset Turnover | - | - | 0.04x | 0.09x | 0.03x | 0.05x | 0.03x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 46.37M | 0 | 0 | 58K | 58K | 0 | 58K |
| Other Non-Current Assets | -4.47M | 0 | 0 | 0 | 0 | 58K | 0 |
| Total Assets | 47.16M | 14.88M | 68.24M | 63.06M | 44.49M | 52.34M | 27.34M |
| Asset Turnover | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
| Asset Growth % | - | -0.68% | 3.59% | -0.08% | -0.29% | 0.18% | -0.48% |
| Total Current Liabilities | 222.24K | 4.31M | 11.67M | 6.03M | 13.86M | 25.33M | 10.29M |
| Accounts Payable | 0 | 889K | 1.12M | 1.92M | 3.01M | 1.5M | 1.24M |
| Days Payables Outstanding | - | 360.54 | 6.31K | 2.43K | 42.31K | 4.54K | 6.47K |
| Short-Term Debt | 3M | 416K | 0 | 0 | 6.42M | 19.5M | 359K |
| Deferred Revenue (Current) | -1000K | 80K | 413K | 0 | 0 | 0 | 1000K |
| Other Current Liabilities | 68K | 2.11M | 7.15M | 520K | 0 | 2.12M | 0 |
| Current Ratio | 3.56x | 2.20x | 5.40x | 9.06x | 2.11x | 1.53x | 1.57x |
| Quick Ratio | 3.56x | 2.19x | 5.38x | 9.05x | 2.10x | 1.53x | 1.56x |
| Cash Conversion Cycle | - | - | -1.4K | -1.56K | -39.42K | -3.68K | -5.69K |
| Total Non-Current Liabilities | 41.94M | 5.68M | 56.23M | 44.44M | 27.4M | 13.62M | 25.9M |
| Long-Term Debt | 0 | 640K | 1.95M | 19.08M | 19.25M | 7.15M | 15.43M |
| Capital Lease Obligations | 224K | 1.82M | 1.99M | 4.47M | 5.59M | 4.9M | 4.13M |
| Deferred Tax Liabilities | -224K | 0 | 260K | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 39.87M | 1.37M | 52.03M | 20.89M | 2.56M | 1.57M | 6.34M |
| Total Liabilities | 42.16M | 9.99M | 67.9M | 50.47M | 41.26M | 38.95M | 36.19M |
| Total Debt | 3.22M | 2.88M | 4.32M | 24.04M | 31.82M | 32.16M | 20.84M |
| Net Debt | 2.48M | -5.91M | -54.95M | -26.25M | 13.49M | 3.34M | 8.69M |
| Debt / Equity | 0.64x | 0.59x | 12.68x | 1.91x | 9.83x | 2.40x | - |
| Debt / EBITDA | 9.26x | - | - | - | - | - | - |
| Net Debt / EBITDA | 7.13x | - | - | - | - | - | - |
| Interest Coverage | - | -185.59x | -21.28x | -57.45x | -14.69x | -8.89x | -8.14x |
| Total Equity | 5M | 4.89M | 341K | 12.6M | 3.24M | 13.39M | -8.86M |
| Equity Growth % | - | -0.02% | -0.93% | 35.94% | -0.74% | 3.14% | -1.66% |
| Book Value per Share | 1.60 | 1.41 | 0.10 | 4.09 | 0.99 | 2.55 | -1.27 |
| Total Shareholders' Equity | 5M | 4.89M | 341K | 12.6M | 3.24M | 13.39M | -8.86M |
| Common Stock | 199 | 2K | 6K | 6K | 7K | 13K | 1K |
| Retained Earnings | 17.04K | -69.57M | -153.56M | -163.3M | -193.22M | -242.72M | -282.12M |
| Treasury Stock | -1.33M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 27.18K | 41K | 325K | 233K | 203K | 199K | 71K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -205.37K | -13.2M | -18.93M | -34.62M | -39.01M | -30.17M | -21.33M |
| Operating CF Margin % | - | - | -91.89% | -47.89% | -82.48% | -46.13% | -62.36% |
| Operating CF Growth % | - | -63.26% | -0.43% | -0.83% | -0.13% | 0.23% | 0.29% |
| Net Income | -277.31K | -16.16M | -19.28M | -9.74M | -29.92M | -49.5M | -39.4M |
| Depreciation & Amortization | 672K | 848K | 963K | 955K | 1.02M | 1.71M | 1.65M |
| Stock-Based Compensation | 269K | 399K | 761K | 12.38M | 8.51M | 9.12M | 7.95M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -46.6K | 554K | 1.97M | -39.23M | -17.09M | 8.7M | 5.26M |
| Working Capital Changes | 118.54K | 1.16M | -3.35M | 1M | -1.54M | -191K | 3.21M |
| Change in Receivables | 0 | 0 | -21K | -28K | -140K | 46K | 79K |
| Change in Inventory | 0 | -28K | -163K | 150K | -2K | 6K | -31K |
| Change in Payables | 0 | -76K | -312K | 1.27M | 285K | -1.51M | -264K |
| Cash from Investing | -46M | -294K | -387K | -1.33M | -10.16M | -1.5M | 6.32M |
| Capital Expenditures | -752K | -294K | -387K | -1.33M | -5.18M | -330K | -15K |
| CapEx % of Revenue | - | - | 1.88% | 1.84% | 10.95% | 0.5% | 0.04% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 46.95M | 5.5M | 69.53M | 27.11M | 17.25M | 42.16M | -1.53M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 15.9M | 610K | 28.55M | -1.98M | 229K | -200K | 124K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -957.37K | -13.49M | -19.32M | -35.96M | -44.19M | -30.5M | -21.34M |
| FCF Margin % | - | - | -93.77% | -49.73% | -93.42% | -46.64% | -62.4% |
| FCF Growth % | - | -13.09% | -0.43% | -0.86% | -0.23% | 0.31% | 0.3% |
| FCF per Share | -0.31 | -3.89 | -5.52 | -11.68 | -13.55 | -5.81 | -3.07 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.82x | 0.98x | 3.55x | 1.30x | 0.61x | 0.54x |
| Interest Paid | 0 | 48K | 39K | 1.09M | 2.32M | 3.06M | 2.61M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -5.55% | -326.79% | -737.45% | -150.56% | -377.9% | -595.47% | -1738.36% |
| Return on Invested Capital (ROIC) | - | -379.33% | - | - | -2357.58% | -181.74% | -299.74% |
| Gross Margin | - | - | 68.45% | 60.03% | 94.5% | 81.5% | 79.53% |
| Net Margin | - | - | -9357.77% | -1347.16% | -6325.16% | -7569.42% | -11520.47% |
| Debt / Equity | 0.64x | 0.59x | 12.68x | 1.91x | 9.83x | 2.40x | - |
| Interest Coverage | - | -185.59x | -21.28x | -57.45x | -14.69x | -8.89x | -8.14x |
| FCF Conversion | 0.74x | 0.82x | 0.98x | 3.55x | 1.30x | 0.61x | 0.54x |
| Revenue Growth | - | - | - | 250.97% | -34.58% | 38.27% | -47.71% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Product | 176K | 570K | 316K | 498K | 237K |
| Product Growth | - | 223.86% | -44.56% | 57.59% | -52.41% |
| Royalty | 30K | 153K | 144K | 156K | 105K |
| Royalty Growth | - | 410.00% | -5.88% | 8.33% | -32.69% |
Clene Inc. (CLNN) reported $0.2M in revenue for fiscal year 2024.
Clene Inc. (CLNN) saw revenue decline by 47.7% over the past year.
Clene Inc. (CLNN) reported a net loss of $30.5M for fiscal year 2024.
Clene Inc. (CLNN) has a return on equity (ROE) of -1738.4%. Negative ROE indicates the company is unprofitable.
Clene Inc. (CLNN) had negative free cash flow of $18.6M in fiscal year 2024, likely due to heavy capital investments.